Document Detail

The role of neuropeptides in suicidal behavior: a systematic review.
Jump to Full Text
MedLine Citation:
PMID:  23986909     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
There is a growing evidence that neuropeptides may be involved in the pathophysiology of suicidal behavior. A critical review of the literature was conducted to investigate the association between neuropeptides and suicidal behavior. Only articles from peer-reviewed journals were selected for the inclusion in the present review. Twenty-six articles were assessed for eligibility but only 22 studies were included. Most studies have documented an association between suicidality and some neuropeptides such as corticotropin-releasing factor (CRF), VGF, cholecystokinin, substance P, and neuropeptide Y (NPY), which have been demonstrated to act as key neuromodulators of emotional processing. Significant differences in neuropeptides levels have been found in those who have attempted or completed suicide compared with healthy controls or those dying from other causes. Despite cross-sectional associations between neuropeptides levels and suicidal behavior, causality may not be inferred. The implications of the mentioned studies were discussed in this review paper.
Authors:
Gianluca Serafini; Maurizio Pompili; Daniel Lindqvist; Yogesh Dwivedi; Paolo Girardi
Related Documents :
8742289 - Subacute hematogenous osteomyelitis: are biopsy and surgery always indicated?
19796469 - Ileal conduit stomal hemorrhage as the first presentation of end stage liver disease: c...
24688369 - A review on using crumb rubber in reinforcement of asphalt pavement.
22952359 - Board invited review: the importance of the gestation period for welfare of calves: mat...
8683269 - Aplasia cutis congenita. case report.
22122389 - Reporting rates of yellow fever vaccine 17d or 17dd-associated serious adverse events i...
22940279 - Drug treatment of multidrug-resistant osteoarticular tuberculosis: a systematic literat...
24223389 - A rare case of laryngotracheal chondrosarcoma in a patient with past history of radioio...
17444339 - Utility of scorpion antivenin vs prazosin in the management of severe mesobuthus tamulu...
Publication Detail:
Type:  Journal Article     Date:  2013-08-06
Journal Detail:
Title:  BioMed research international     Volume:  2013     ISSN:  2314-6141     ISO Abbreviation:  Biomed Res Int     Publication Date:  2013  
Date Detail:
Created Date:  2013-08-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101600173     Medline TA:  Biomed Res Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  687575     Citation Subset:  IM    
Affiliation:
Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, 1035-1039 Via di Grottarossa, 00189 Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Biomed Res Int
Journal ID (iso-abbrev): Biomed Res Int
Journal ID (publisher-id): BMRI
ISSN: 2314-6133
ISSN: 2314-6141
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2013 Gianluca Serafini et al.
open-access:
Received Day: 27 Month: 4 Year: 2013
Revision Received Day: 1 Month: 7 Year: 2013
Accepted Day: 3 Month: 7 Year: 2013
Print publication date: Year: 2013
Electronic publication date: Day: 6 Month: 8 Year: 2013
Volume: 2013E-location ID: 687575
PubMed Id: 23986909
ID: 3748411
DOI: 10.1155/2013/687575

The Role of Neuropeptides in Suicidal Behavior: A Systematic Review
Gianluca Serafini1* http://orcid.org/0000-0003-1389-0084
Maurizio Pompili1
Daniel Lindqvist2 http://orcid.org/0000-0002-3472-327X
Yogesh Dwivedi3
Paolo Girardi1
1Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant'Andrea Hospital, Sapienza University of Rome, 1035-1039 Via di Grottarossa, 00189 Rome, Italy
2Department of Clinical Sciences, Section of Psychiatry, Lund University, SE-221 85 Lund, Sweden
3Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
Correspondence: *Gianluca Serafini: gianluca.serafini@uniroma1.it
[other] Academic Editor: Rajnish Chaturvedi

1. Introduction

Suicide represents one of the leading causes of premature death in the general population. Higher suicide rates have generally been reported in men compared to women in almost all countries, with elderly men at especially high risk for completed suicide [13]. Rates of attempted suicide average 20–30 times higher than rates of completed suicide in the general population but are probably underreported and range widely in method and seriousness of intent [4, 5]. Most cases of suicide involve psychiatric conditions, nearly half of which (48.5%) suffered from mood disorders [6].

Major depressive disorder (MDD) is a chronic and invalidating disease associated with significant functional impairment and occupational disability. Individuals with MDD are at increased risk for suicidal behavior [713]. Impulsivity and loss of impulse control may be considered important dimensions of suicidality. As opposed to psychiatric disorders such as MDD that may be regarded as more proximal risk factors for suicide, some have suggested that impulsivity may be seen as a personality characteristic and thus a more distal risk factor for suicide [14]. Yet others have emphasized the importance to distinguish between attempt impulsivity (state) and attempter impulsivity (trait) in understanding suicide attempts [15]. Impulsive personality characteristics have been associated with a higher likelihood of suicidal behavior across nosological entities and also in nonpsychiatric populations [16]. The structure of impulsivity in severe depression as well as its relationships to suicide attempts have been investigated by Corruble et al. [17]. They found that recent suicide attempts in severely depressed individuals were related to loss of control and cogntive impulsivity but not to nonplanning. The tendency to engage in more impulsive behaviors, reflecting possible loss of impulse control, may be assessed using the impulse control scale [18]. Behavioral loss of control has been found as a state-dependent dimension of impulsivity and suicide attempts were mainly related to loss of control in depressed patients. The planning subscale of the suicide intent scale [19] can be used to objectify degree of impulsivity during a suicide attempt.

Despite the recent advancements in the understanding of suicide, our current knowledge concerning the neurobiology of this complex phenomenon is still limited.

Peptide hormones might play a critical role in normal as well as pathological functions of the central nervous system [20, 21] acting as selective messengers in specific emotive circuits of the brain [22] and function as crucial mediators of the stress response and adaptation [23]. Neuropeptides show high specificity for their target receptors and are highly potent; also, they are not accumulated in tissues as they are efficiently metabolized by endogenous enzymes [20]. They generally interact with metabotropic or G-protein-coupled receptors, whereas neurotransmitters are chemical substances that affect the excitability of neurons acting as mediators of the neurotransmission through synapses. Neuropeptides are generally stored in large dense-core vesicles; conversely, neurotransmitters are secreted in small synaptic vesicles mainly located in clusters at presynaptic locations. It has been suggested that peptide signals play a prominent role in the information processing, that is, quite unlike that of conventional neurotransmitters [24].

Neuropeptides may modulate a more prolonged transmission than typical neurotransmitters showing relevant neurotrophic effects [25]. Neuropeptides are mainly associated with one or more neurotransmitters which serve to integrate their modulatory functions. The high frequency release of neuropeptides is in line with the ability to mediate adaptation to homeostatic challenges [23]. Some authors suggested that cholecystokinin (CCK) and neuropeptide Y (NPY) are promising options for the discovery of intriguing and more selective pharmacological options [26]. Other neuropeptides like corticotropin-releasing factor (CRF) and neurokinin 1 (NK1) substance P systems are known to modulate 5HT neurons through actions within the dorsal raphe (DR) networks [27]. A hyperactivity of central neuropeptidergic circuits such as CRF and arginine vasopressin (AVP) systems may play a key role in major affective and anxiety disorders [25, 28, 29]. These neuropeptidergic systems may be involved in the action of antidepressant drugs, as demonstrated by the paroxetine-induced reduction of vasopressinergic overexpression [30]. Neuropeptides dysregulation may be also involved in suicidal behavior. Sherrin et al. [31] compared CCKB receptor gene expression in ten suicide victims compared with ten matched controls using quantitative PCR and showed increased gene expression in suicide victims in prefrontal and cingulate cortex as well as cerebellum. This study was in line with previous results demonstrating increased CCK receptor binding in frontal and cingulated cortex of suicide victims [32]. Also, recent suicide attempts have been associated with lower plasma levels of NPY [33]. Lower NPY levels have been found in prefrontal cortex and caudate nucleus of suicide victims compared to age-matched subjects with other causes of death [34]. Reduced NPY levels, which are widely distributed throughout the central nervous system, have been found in depressed patients compared to controls [35], as well as in the brain of suicide victims compared to those who died a natural or accidental death [34].

To what extent neuropeptide abnormalities may be considered reliable predictors of suicidal behavior is, however, a matter of debate. Considering this background, we aimed to critically review the current literature about the role of neuropeptides in suicidal behavior.


2. Methods
2.1. Information Sources, Search Strategy, and Study Selection

A detailed search strategy summarized in Figure 1 was used to identify relevant studies. The possible involvement of neuropeptides in suicidal behavior was investigated using a detailed PubMed/MEDLINE, Scopus, PsycLit, and PsycInfo search to identify all papers and book chapters in English language during the period between January 1985 and January 2013. The search used a combination of the following terms: “Neuropeptides” OR “Central nervous System Peptides” OR “Small bioactive peptides” AND “Suicid*” (including suicidal behaviors OR suicide ideation OR suicidal thoughts OR deliberate self-harm OR suicidal attempts). Two independent researchers conducted a two-step literature search. Any discrepancies between the two reviewers who, blind to each other, examined the studies for the possible inclusion were resolved by consultations with a senior author. The reference lists of the articles included in the review were also manually checked for relevant studies.

Studies were included according to the following criteria: (a) being an original paper in a peer-reviewed journal and (b) have analyzed the possible involvement of neuropeptides in suicidal behavior. Figure 1 summarized the search strategy used for selecting studies (identification, screening, eligibility, and inclusion process) in the review.

2.2. Study Design and Eligibility Criteria

To achieve a high standard of reporting, we have adopted Preferred Reporting Items for Systematic Reviews and Meta-Analyses, (PRISMA) guidelines [36]. The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram for reporting in systematic reviews and meta-analyses. PRISMA includes the broader effort to improve the reporting of different types of health research and in turn to improve the quality of research used in decision making in healthcare.

2.3. Recorded Variables

The recorded variables for each article about neuropeptides and suicide were sample characteristics, study design, type of neuropeptide which has been investigated, main findings, limitations, and conclusions (Table 2).


3. Results
3.1. Number of Studies Selected

The combined search strategies yielded a total of 185 articles of which, after a complete analysis, 26 full-text articles were screened and considered for the inclusion in the current review. 159 studies were excluded because they were considered not relevant to the main topic. Specifically, we excluded articles not published in peer reviewed journals and not in English language, articles without abstracts, abstracts that did not explicitly mention the link between neuropeptides and suicide, articles with a publication date before 1985, and those with unclear data regarding materials and methods and number of patients analyzed. As mentioned, we assessed 26 articles for eligibility but 4 full-text articles were excluded due to low relevance to the main theme leaving 22 studies that fulfilled our inclusion criteria.

3.2. Corticotropin-Releasing Factor (CRF), Oxytocin, and Arginine Vasopressin (AVP)

CRF, oxytocin, and AVP have been hypothesized to play a crucial role in the pathogenesis of major affective disorders and presumably suicidal behavior.

Clinical and basic research supports the notion that these neuropeptides appear crucial in modulating behavior. During the past decade, drug discovery efforts using neuropeptide receptor ligands have focused on a limited number of neuropeptides, such as CRF, oxytocin, and AVP although many other neuropeptide systems have been identified. Table 1 summarized the large body of evidence suggesting the involvement of CRF, oxytocin, and AVP in major affective disorders and suicidal behavior.

3.3. Galanin

Galanin (GAL) is a 30-amino-acid peptide that binds GAL receptor1 (R1), GALR2, and GALR3 found along the HPA axis and involved in several human functions such as food and alcohol intake, metabolism, osmoregulation, seizure threshold, and reproduction. Depression-like behaviors seem to be induced by the activation of GALR1 and attenuated depression-like behaviors derived by the activation of GALR3 [103]. GAL immunoreactivity has been showed in human midbrain and limbic areas [104]. Although several studies sustained a role of GAL in the hypothalamic-pituitary-adrenal (HPA) axis activity, findings about this association are quite conflicting [105]. GAL has been reported to modulate serotonergic and noradrenergic circuits [106] as well as GAL transmission (related to the inhibition of dopaminergic neurons in the ventral tegmental area) mediating anhedonia and reduced locomotor activity in depressed patients enhanced locus coeruleus (LC) hyperactivity [107]. GAL antagonists have been reported to improve these effects [107]. The expression of somatodendritic 5HT1a autoreceptors (significantly involved in the pathophysiology of major depression) in the DR nucleus may be modified by GAL with a consequent enhancement of serotonergic transmission [108]. Anxiolytic and antidepressant properties have been reported using GALR3 antagonists in animal models [109]. Finally, evidence suggested that activation of GALR2 is associated with neurogenesis and neuroprotective effects improving hippocampal damage which was commonly found after chronic depression [110].

3.4. Substance P

SP that binds three different g-protein-coupled tachykinin receptors—NK1, NK2, and NK3, has been associated with nociception, respiration, cardiovascular and thermoregulation, gut motility, emetic response, and stress-related disorders [111]. The SP/NK1 system modulates central noradrenergic and serotonergic circuits. Serotonergic activity in the hippocampus and lateral septum was enhanced by NK1 antagonism [112]. NK1 immunoreactivity has been found in the noradrenergic neurons of LC [113]. Several studies sustained a role of SP/NK1 system in the HPA axis and stress responsiveness but not all studies confirmed these findings [111]. Stressful situations may stimulate SP/NK1 system and enhance SP release in the hypothalamus, amygdala, lateral septum, nucleus accumbens, and LC [114]. Animal models have shown that NK1 antagonist may reduce anxiogenic effects related to the injection of SP in the central nucleus of the amygdala [115] showing antidepressant properties [116]. Furmark et al. [117] using functional imaging also suggested that NK1 antagonism in humans reduced social anxiety related to the modulation of serotonergic circuits. NK1 antagonists represent promising medications with consistent antidepressant and anxiolytic properties. There are, however, conflicting results based on the main studies [114, 115] measuring SP levels among psychiatric patients and controls. Animal models of anxiety and depression have shown preclinical efficacy by NK2 antagonists [118] whereas NK3 receptors might be valid targets for antipsychotic treatment [119].

3.5. Neuropeptide Y

NPY is a 36-amino-acid which is involved in circadian rhythms, neurogenesis and neuroprotection, nociception, feeding behavior and energy regulation, neuronal excitability, emotion and cognition, stress response, and resilience. NPY action is associated with several neurotransmitters such as GABA, serotonin, norepinephrine, and other catecholamines [120, 121]. The central NPY transmission has been associated with anxiolytic and antidepressant properties in animal models [122]. Anxiolytic and antidepressant effects have been demonstrated after the activation of receptors Y1 in animals [123] whereas the activation of Y2 is related to anxiogenic effects [124]. Recently, conflicting results have emerged after activation or Y5 antagonism [125].

The enhanced NPY transmission might be stimulated to control stress response through the modulation of CRF and noradrenergic tone. In fact, the reduced NPY transmission may be related to increased CRF and noradrenergic transmission determining anxiety and depression behaviors [126]. NPY, no doubt, has important and complex interactions with the CRF system. Sajdyk et al. [127] suggested that NPY is associated with anxiolytic activity in the amygdala where both CRF receptors and high concentrations of NPY have been found. However, mixed findings regarding NPY levels have been reported among humans [128].

3.6. Cholecystokinin

CCK is a 33-amino-acid peptide that has been found to be implicated in gastric emptying, gallbladder contraction, pancreatic enzyme release, and suppression of appetite. CCK levels were observed in the cortex, hippocampus, amygdala, nucleus accumbens, striatum, and substantia nigra [129]. CCKR1 and CCKR2, with the latter predominantly expressed in the brain, have been described as the 2 G-protein coupled receptors binding CCK. Relevant effects on behaviors which are known to be mediated via dopamine seem to be induced by CCK peptides.

The interaction of CCK with CCKR2 has been reported to inhibit dopamine release blocking dopamine-mediated behaviors into the anterior nucleus accumbens whereas the binding with CCKR1 into the posterior nucleus accumbens is associated with opposite effects [130, 131]. CCK agonists that may be active in the treatment of schizophrenia should be nonselective or CCKR1 selective. Overall, there are evidence suggesting that CCK may be involved in both affective- and stress-related disorders.

3.7. Dynorphins

The complete sequence of dynorphin A (Dyn-A) (17amino acids) was identified by Goldstein et al. [132] in 1981. The prefix dyn—was taken from the Greek (power) whereas—orphin suggests its opioid nature. Dyn-A might play a regulatory role in epilepsy and addiction, whereas findings related to emotional control are quite conflicting. Data are mainly derived from animal models and a correct interpretation of findings from mouse testing has to be observed in the general context of a different social behavior in rats and mice [133]. Exploring the effects and molecular mechanism of action of dynorphins in humans is a very complicated task considering mood and anxiety behaviors that may be investigated only indirectly through a detailed interpretation of animal models.

3.8. Orexin

Orexins or hypocretins and their receptors have been discovered in 1998 as predominantly expressed in the lateral hypothalamus [134], specifically in the perifornical region of the lateral hypothalamus and the posterior hypothalamic area [135, 136]. The name hypocretins is related to the similar amino acid sequence of the gut peptide secretin, whereas the name orexins is derived by the Greek word orexis which means appetite (these are peptides that stimulate food intake) [137].

Hypocretin fibers such as the central nucleus of the amygdala (CeA), bed nucleus of the stria terminalis (BNST), LC, and paraventricular nucleus of the hypothalamus (PVN) might have a specific role in the regulationof stress responses [136]. Hypocretins bind the hypocretin-1 and hypocretin-2 receptors. Hypocretin-1 has a 2-3-fold higher affinity for the hypocretin-1 receptor than hypocretin-2 [137]. Several studies have provided evidence for a role of orexins/hypocretins in the regulation of stress responses and in the regulation of many human behaviors.

3.9. The Association between Neuropeptides and Suicidality

Neuropeptides may play a key role in the stress response as well as in the regulation of several human behaviors. Table 2 summarized the most relevant studies addressing the association between neuropeptides and suicide.

Important insight into the role of neuropeptides in the pathogenesis of MDD and suicidal behavior has been given. Orexin alterations have been investigated in several subgroups of patients. In a factor analysis of CSF biomarkers in suicide attempters, a negative loading on orexin, along with positive loading on proinflammatory cytokine interleukin-6 and monoamine metabolites 5-HIAA and HVA was associated with violent suicide method and risk for future suicide completion [83]. Orexin levels were also reported to be significantly lower in patients with MDD compared to those with adjustment disorder and dysthymia [87]. The same research group has also found that lower orexin levels were associated with depressive symptoms such as higher inertia and decreased motor activity in 101 suicide attempters [88]. As later reported by Brundin et al. [85], a significant negative correlation was found between the change in CSF-orexin levels and symptoms of suicidality, assessed by SUAS [138], one year after a suicide attempt.

Furthermore, Inder et al. [93] found a significant positive correlation between plasma AVP, ACTH, and cortisol levels in depressed subjects. The authors reported that plasma AVP levels were increased in those subjects who had attempted suicide whereas no difference was observed in mean cortisol between depressed subjects and controls.

Patients with NSSI were also investigated in order to find abnormalities in neuropeptides. Stanley et al. [84] recruited 29 psychiatric patients with a history of one or more suicide attempts with a mean of three attempts. Patients with NSSI had lower CSF β-endorphin levels and met-enkephalin when compared to a diagnostically matched group of patients without NSSI but no difference in dynorphin levels was found between the two groups.

The excessive CRH secretion and neurotransmission which is involved in the pathophysiology of depressive disorders has been suggested to extend beyond the hypothalamus and to involve several extrahypothalamic brain regions. Austin et al. [89] found a significant positive correlation between the magnitude of the increase in CRH-IR levels in the LC and the age at illness onset in a sample of 11 depressed subjects who died by suicide compared with controls. Specifically, the mean level of CRH-IR in depressed subjects was significantly increased by 30% in the LC, by 45% in the caudal nucleus of the DR and by 39% in the median raphe relative to healthy controls.

In addition, Träskman-Bendz et al. [100] reported that, in a sample of 44 suicide attempters, patients who had made previous suicide attempts had significantly lower CRH than those who had not, and only patients with MDD had significantly lower somatostatin, CRH, and DSIP compared to patients with other diagnoses. Westrin et al. [95] found that levels of CSF-somatostatin, but not CSF-CRH, increased with clinical improvement in suicidal patients independently of psychiatric diagnoses.

Westrin et al. [96] found that in a sample of 34 MDD suicidal patients, those with previous suicide attempts had increased plasma DSIP levels. Scarone et al. [101] suggested reduced beta-endorphin levels in the left temporal cortex, frontal cortex, and caudate nucleus in 7 suicides compared to 7 controls. An asymmetrical concentration of beta-endorphins in suicides (left less than right) was also suggested in frontal cortex and caudate nucleus.

Whether psychoactive treatments affect neuropeptides levels is a matter of debate. Olsson et al. [94] found that antidepressant treatment seemed to affect the levels of CSF NPY and SP. Westrin et al. [33] suggested that there may be alterations in CRH and NPY plasma levels in patients with a mood disorder who had recently attempted suicide. Specifically, the authors found that cortisol was significantly high and CRH and NPY were low in recent suicide attempters. Moreover, Westrin et al. [97] reported that NPY correlated positively with psychasthenia, irritability, and stability in patients and negatively with muscular tension, psychasthenia, verbal aggression, and irritability in controls. Cortisol correlated positively with validity, extraversion, and verbal aggression and negatively with inhibition of aggression in controls.

Also, post-mortem studies have been conducted in order to analyze the possible role of neuropeptides in suicidal behavior. Merali et al. [90] suggested that in a sample of 30 suicides and 37 controls, suicides were associated with site-specific alterations in the endogenous levels of CRH, AVP, GRP, and NMB. However, GRP and NMB variations were limited although GRP-ir within the LC of suicides was higher than in control subjects and NMB-ir which was reduced at the DVC of suicides. In another post-mortem study, Caberlotto and Hurd [92] reported that no significant alterations in Y1 or Y2 mRNA expression levels were observed between suicides and controls. The Y2 mRNA expression was increased in layer IV of suicides. There was a negative correlation between Y1 mRNA expression levels in the prefrontal cortex and increasing age.

Moreover, Widdowson et al. [34] reported the existence of NPY deficit in the brain leading to region-specific reductions in neuropeptide concentrations in individuals with a history of depression. In this post-mortem study, the authors found that NPY levels were significantly lower in the frontal cortex and caudate nucleus of suicide victims compared to age-matched controls.

Negative findings have also been reported. Pitchot et al. [86] found no correlation between severity of depressive symptoms and AVP-neurophysins or post-DST cortisol levels in a sample of 28 MDD inpatients. Any correlation between AVP-neurophysins and post-DST cortisol levels (r = −0.07, P = 0.72) was observed. AVP neurophysins did not differ between DST suppressors and nonsuppressors. In addition, Brunner et al. [91] found no differences in CSF AVP concentrations between 19 depressed suicide attempters, depressed nonsuicidal patients, and 9 neurological control subjects and there was no relationship between CSF AVP and monoamine metabolites in CSF.

In a 5-year follow-up study, Roy [98] did not find evidence that NPY, somatostatin, diazepam-binding inhibitor, GABA, or CRH were major determinants of suicidal behavior or its repetition in depression, since no significant differences between depressed patients who did or did not reattempt suicide were found. Also, Ordway et al. [99] found no significant differences in NPY concentrations between suicide victims with MDD (with comorbid alcohol dependence) and age-matched control subjects. Finally, Maes et al. [102] reported no significant differences in TSH, FT4, ACTH, and total L-TRP levels between patients with suicidal ideation and those without.


4. Discussion

The present review supports a role of neuropeptides in the pathophysiology of suicidal behavior. Based on the included studies, there may be associations between neuropeptides and suicidal behavior but this does not imply the existence of a causal link. Most studies (thirtheen) [33, 34, 8385, 89, 90, 9296, 101] included in our review found an association between neuropeptides and suicidal behavior; however, there are also six studies [86, 91, 98100, 102] that did not confirm this association. Moreover, there are other studies suggesting that neuropeptides abnormalities may be found in subjects with MDD but not suicidal behavior [87, 88, 97].

One relevant limitation of the selected studies is related to the variable neuropeptide concentrations (e.g., some studies reporting increases and others reporting reductions or no significant changes) in those who attempted suicide or died by suicide compared with healthy controls or those dying a sudden natural or accidental death, respectively. These findings reflected the significant heterogeneity in terms of psychopathology which is commonly observed in those with suicidal behavior together with the variability in the antidepressant response which may be found in these different subgroups of patients. Specific stressors may induce specific neuropeptide responses: SP may be evoked by structural damage, oxytocin release by social threats, melanin-concentrating hormone (MCH) by abnormal energy homeostasis, and AVP changes by blood volume changes, respectively. Neuropeptides such as CRF, VGF, CCK, SP, and NPY have been demonstrated to act as key neuromodulators of emotional processing [139, 140].

Neuropeptides may be considered as crucial molecules in the interaction between genes and environment as well as fundamental mediators of the stress response able to in turn affect gene regulation in order to respond to the different environmental stimuli. What is the main mechanism underlying neuropeptides alterations in subjects with suicidal behavior? Evidence suggests that modulation of monoaminergic transmission may represent the main mechanism by which the neuropeptide galanin was implicated in stress-related disorders [103]. This modulation of monoaminergic systems has been observed predominantly in the LC and DR nuclei. At the molecular level, stressful events may enhance the expression of tyrosine hydroxylase [141143], the enzyme which is involved in controlling catecholamine synthesis, and GAL [103, 144] with the final increase of noradrenergic transmission. This may determine both direct and indirect inhibitory effects on postsynaptic neuronal functions implicated in depression-like behaviors.

The role of NPY and its receptors in affective disorders and stress-related conditions has been investigated for over two decades but still remains rather controversial. According to behavioral findings on NPY, Y1, and Y2 receptors in animal models, evidence suggested an important role of NPY in emotional responses and stress- or depression-related disorders [145]. Westrin et al. [33] reported significantly higher cortisol, CRH, and lower NPY levels in recent suicide attempters when compared with healthy controls. NPY was also reported by the same research group to correlate positively with psychasthenia, irritability, and stability and negatively with validity in patients [97]. There are also studies that did not report significant changes in neuropeptides concentrations in patients with suicidal behavior. There were no significant differences in CSF NPY, somatostatin, diazepam-binding inhibitor, GABA, or CRH levels between depressed patients who did or did not reattempt suicide during the follow-up or those who had never attempted according to Roy [98]. However, a nonsuicidal control group was not included in the mentioned study. Moreover, Ordway et al. [99] did not find an association between NPY and completed suicide, although the fact that some suicide victims had a history of comorbid alcohol dependency who may have confounded the results.

Pitchot and colleagues [86] found no association between major depressive symptoms as assessed by HDRS and AVP-neurophysins levels. However, the authors of this study stated that plasma AVP levels presumably did not reflect AVP activity in the mangocellular portion of the paraventricular nucleus. Also, no significant difference in dynorphin levels was found between patients with a history of one or more suicide attempts [84]. Here, it is important to note that plasma neuropeptide levels may not accurately reflect central neuropeptide levels. In addition, Westrin et al. [95] found no significant changes in CSF-CRH at follow-up in 16 patients of which eleven had made previous suicide attempts. However, the substances which have been ingested by patients may have caused the initially low CRH and somatostatin levels, and thus confounded the results. Furthermore, this study did not demonstrate whether somatostatin changes are specifically related to either suicidality or depression but only that somatostatin changes are related to clinical symptomatic recovery in suicidal patients.

Finally, based on Maes et al. investigation [102], no relevant (significant) differences were observed in terms of TSH, FT4, pre- and postdexamethasone cortisol, ACTH, and L-TRP levels between patients with suicidal ideation and those without. However, considering the possible caveats, this study was cross-sectional in nature and subjects were not assessed using psychometric instruments.

Many of the mentioned studies should be considered in the light of the following shortcomings. Many studies were not completely informative over time and lacked adequate long-term follow-up periods. The naturalistic designs may not completely control for the effect of confounding factors such as the duration of treatment and disease and the diagnostic subtypes. Also, samples were often too small or included mixed, heterogeneous patients and usually did not allow to generalize findings. Patients with suicidal behavior who were included in these studies may be affected by different psychiatric disorders; the methods of suicide attempts were not controlled in all studies. Differences may exist between participants and those that did not accept to participate in the studies. Furthermore, some of these studies may lack a control group or, alternatively, controls were not matched for age and other clinically relevant information. In addition, psychometric instruments evaluating suicide risk were not used in all studies.

Moreover, many of the observed abnormalities in neuropeptides concentrations were found in subjects with suicidal behavior who were also depressed. It is possible that the association between neuropeptides and suicidality may be mediated by the existence of psychiatric conditions such as major affective disorders. Generally, the variability in the concentrations of neuropeptide markers is too great to draw any definitive conclusion in those who were depressed and also displayed suicidality.

In light of recent advances in understanding the regulation of genes encoding neuropeptides, neuropeptide receptors have emerged as attractive targets for the treatment of many psychiatric disorders. To date, many molecules have been synthesized but none has been introduced into the market due to the failure of most clinical trials aimed to show their efficacy. Griebel and Holsboer [146] stated in their review that although no strong mechanistic hypothesis supports the active role of the neuropeptide system in psychiatric conditions, medications targeting neuropeptide receptors have not completely failed to demonstrate their efficacy. They analyzed preclinical and clinical evidence on nonpeptidergic ligands for neuropeptide receptors in psychiatric disorders mainly focusing on tachykinins, CRF, vasopressin, and neurotensin. Overall, the authors suggested the clinical potential of neuropeptide receptor antagonists as candidate medications that may help to reduce the toll of major affective disorders and suicide but reported the importance to stratify patients according to the different subtypes and illness severity. Objectifiable laboratory tests should be available to go beyond the issue of heterogeneity of patients recruited in the different studies. Moreover, the authors recommended the careful knowledge of DNA sequence variations of neuropeptides and they highlighted the importance to ensure that abnormalities in neuropeptide signalling represent one of the most relevant pathogenetic factors in major depression.

Biomarkers and genetic tests are suggested to identify clinical conditions that may be related to a specific neuropeptidergic mechanism. The specificity of the mechanism of action of the different neuropeptides should also be adequately considered. An important research question that needs to be addressed in future studies is how and when personalizing treatments using drugs targeting neuropeptide receptors are possible. This implies the knowledge of whether subjects could preferably respond to a medication or another, which may be the right combination of medications, and what is the real benefit for some subgroups of patients.

The possibility to select medications targeting neuropeptide receptors according to findings derived from animal studies should be carefully considered using models evaluating different aspects of the disorders.

A detailed characterization of patients based on objectifiable measures, genetic tests, and reliable biomarkers is undoubtedly requested.


5. Conclusion

According to most of the studies included in the present review, neuropeptides may play a key role in the pathophysiology of suicidal behavior. In particular, one mechanism by which neuropeptide alterations may promote suicidal symptoms is via changes in monoaminergic systems rendering neuropeptides as novel, intriguing mediators of stress-related and affective conditions as well as suicidality.

However, despite the recent advances in this research field, it is unlikely that neuropeptides represent definitive and reliable markers of suicidality. Further additional studies will elucidate the pathophysiological mechanisms of the different neuropeptides pathways underlying suicidal behavior.


References
1. Goldsmith SK,Pellmar TC,Kleinman AM,Bunney WE. Reducing SuicideYear: 2002Washington, DC, USAInstitute of Medicine of the US National Academies of Science
2. Simon RI,Hales RE. Textbook of Suicide Assessment and ManagementYear: 2006Washington, DC, USAAmerican Psychiatric Press
3. World Health Organization (WHO)International suicide rates http://www.who.int/mental_health/prevention/suicide/country_reports/en/index.html.
4. Tondo L,Isacsson G,Baldessarini RJ. Suicidal behaviour in bipolar disorder: risk and preventionCNS DrugsYear: 20031774915112-s2.0-003828151512751919
5. Kessler RC,Berglund P,Borges G,Nock M,Wang PS. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003Journal of the American Medical AssociationYear: 200529320248724952-s2.0-1894436863615914749
6. Roy A. Sadock BJ,Sadock VASuicideKaplan and Sadock’s Comprehensive Textbook of PsychaitryYear: 200027th editionPhiladelphia, Pa, USALippincott Willians and Wilkins20312040
7. Pompili M,Innamorati M,Rihmer Z,et al. Cyclothymic-depressive-anxious temperament pattern is related to suicide risk in 346 patients with major mood disordersJournal of Affective DisordersYear: 201213634054112-s2.0-8485736737522177743
8. Pompili M,Rihmer Z,Akiskal H,et al. Temperaments mediate suicide risk and psychopathology among patients with bipolar disordersComprehensive PsychiatryYear: 20125332802852-s2.0-8485879693121641589
9. Pompili M,Serafini G,Innamorati M,et al. Suicide risk in first episode psychosis: a selective review of the current literatureSchizophrenia ResearchYear: 201112911112-s2.0-7995613444421530179
10. Serafini G,Pompili M,Innamorati M,et al. Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disordersJournal of Affective DisordersYear: 20111291-347552-s2.0-7985151479420708276
11. Serafini G,Pompili M,Innamorati M,et al. The role of microRNAs in synaptic plasticity, major affective disorders and suicidal behaviorNeuroscience ResearchYear: 2012731791902-s2.0-8486056164722521503
12. Innamorati M,Pompili M,Gonda X,et al. Psychometric properties of the Gotland Scale for Depression in Italian psychiatric inpatients and its utility in the prediction of suicide riskJournal of Affective DisordersYear: 20111321-2991032-s2.0-7995812959121371756
13. Maris RW. SuicideThe LancetYear: 200236093293193262-s2.0-0037183246
14. Hawton K,van Heeringen K. SuicideThe LancetYear: 20093739672137213812-s2.0-64349104074
15. Baca-Garcia E,Diaz-Sastre C,García Resa E,et al. Suicide attempts and impulsivityEuropean Archives of Psychiatry & Clinical NeuroscienceYear: 200525521521562-s2.0-1764438225615549343
16. Gvion Y,Apte A. Aggression, impulsivity, and suicide behavior: a review of the literatureArchives of Suicide ResearchYear: 2011152931122-s2.0-7995608230921541857
17. Corruble E,Benyamina A,Bayle F,Falissard B,Hardy P. Understanding impulsivity in severe depression? A psychometrical contributionProgress in Neuro-Psychopharmacology & Biological PsychiatryYear: 20032758298332-s2.0-004313376612921916
18. Plutchik R,Van Praag HM. The measurement of suicidality, aggressivity and impulsivityClinical NeuropharmacologyYear: 19869supplement 4S380S382
19. Beck AT,Herman I,Schuyler D. Beck AT,Resnick HLP,Lettieri DDevelopment of suicidal intent scalesThe Prediction of SuicideYear: 1974Charles Press4546
20. McGonigle P. Peptide therapeutics for CNS indicationsBiochemical PharmacologyYear: 20128355595662-s2.0-8485610358022051078
21. Keck ME,Ohl F,Holsboer F,Müller MB. Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disordersNeuroscience & Biobehavioral ReviewsYear: 2005294-58678892-s2.0-1994441403315899517
22. Panksepp J. The neurochemistry of behaviorAnnual Review of PsychologyYear: 198637771072-s2.0-0022583868
23. Alldredge B. Pathogenic involvement of neuropeptides in anxiety and depressionNeuropeptidesYear: 20104432152242-s2.0-7795120476920096456
24. Ludwig M. Are neuropeptides brain hormones?Journal of NeuroendocrinologyYear: 20112343813822-s2.0-7995264276821435042
25. Hökfelt T,Broberger C,Xu Z-QD,Sergeyev V,Ubink R,Diez M. Neuropeptides—an overviewNeuropharmacologyYear: 2000398133713562-s2.0-004313115310818251
26. Harro J. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategiesAmino AcidsYear: 20063132152302-s2.0-3374955585116738800
27. Valentino RJ,Commons KG. Peptides that fine-tune the serotonin systemNeuropeptidesYear: 2005391182-s2.0-1464444295515627494
28. Gold PW,Chrousos G,Kellner C,et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factorAmerican Journal of PsychiatryYear: 198414156196272-s2.0-00212821066324597
29. Holsboer F. The corticosteroid receptor hypothesis of depressionNeuropsychopharmacologyYear: 20002354775012-s2.0-003379744511027914
30. Keck ME,Welt T,Müller MB,et al. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat modelNeuropsychopharmacologyYear: 20032822352432-s2.0-003731162912589376
31. Sherrin T,Heng KYC,Zhu YZ,Tang YM,Lau G,Tan CH. Cholecystokinin-B receptor gene expression in cerebellum, pre-frontal cortex and cingulate gyrus and its association with suicideNeuroscience LettersYear: 200435721071102-s2.0-124226980615036586
32. Harro J,Marcusson J,Oreland L. Alterations in brain cholecystokinin receptors in suicide victimsEuropean NeuropsychopharmacologyYear: 19922157632-s2.0-00268303651638175
33. Westrin Å,Ekman R,Träskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attemptEuropean NeuropsychopharmacologyYear: 1999932052112-s2.0-003304455010208289
34. Widdowson PS,Ordway GA,Halaris AE. Reduced neuropeptide Y concentrations in suicide brainJournal of NeurochemistryYear: 199259173802-s2.0-00266899531613514
35. Heilig M. Colmers WF,Wahlestedt CNeuropeptide Y in relation to behaviour and psychiatric disordersBiology of Neuropeptide Y and Related PeptidesYear: 1993Totowa, NJ, USAHumana Press511554
36. Moher D,Cook DJ,Eastwood S,Olkin I,Rennie D,Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM GroupThe British Journal of SurgeryYear: 20008711144814542-s2.0-003432007411091231
37. Heinrichs SC,Koob GF. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulationJournal of Pharmacology and Experimental TherapeuticsYear: 200431124274402-s2.0-464428570915297468
38. Nemeroff CB,Vale WW. The neurobiology of depression: inroads to treatment and new drug discoveryJournal of Clinical PsychiatryYear: 200566supplement 75132-s2.0-2514444163016124836
39. Kehne JH. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disordersCNS & Neurological Disorders—Drug TargetsYear: 2007631631822-s2.0-3425031698417511614
40. Pompili M,Serafini G,Innamorati M,et al. The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide preventionEuropean Archives of Psychiatry & Clinical NeuroscienceYear: 201026085836002-s2.0-7875157603220174927
41. Nemeroff CB,Bissette G,Akil H,Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, β-endorphin and somatostatinBritish Journal of PsychiatryYear: 199115859632-s2.0-00260274621673078
42. Stout SC,Owens MJ,Nemeroff CB. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatmentJournal of Pharmacology and Experimental TherapeuticsYear: 20023003108510922-s2.0-003617530911861819
43. Holsboer F. The corticosteroid receptor hypothesis of depressionNeuropsychopharmacologyYear: 20002354775012-s2.0-003379744511027914
44. Nemeroff CB,Widerlov E,Bissette G. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patientsScienceYear: 19842264680134213442-s2.0-00217146066334362
45. Bissette G,Klimek V,Pan J,Stockmeier C,Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjectsNeuropsychopharmacologyYear: 2003287132813352-s2.0-004242340512784115
46. Merali Z,Du L,Hrdina P,et al. Dysregulation in the suicide brain: mRNA expression of corticotropinreleasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain regionJournal of NeuroscienceYear: 2004246147814852-s2.0-124231419714960621
47. Nemeroff CB,Owens MJ,Bissette G,Andorn AC,Stanley M. Reduced corticotropin releasing factor binding sites in the frontral cortex of suicide victimsArchives of General PsychiatryYear: 19884565775792-s2.0-00239273202837159
48. Makino S,Smith MA,Gold PW. Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levelsEndocrinologyYear: 19951368329933092-s2.0-00291266927628364
49. Forster GL,Pringle RB,Mouw NJ,et al. Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activityEuropean Journal of NeuroscienceYear: 20082822993102-s2.0-4824909040818702701
50. Liu Z,Zhu F,Wang G,et al. Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depressionNeuroscience LettersYear: 200640433583622-s2.0-3374631703116815632
51. Liu Z,Zhu F,Wang G,et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disordersNeuroscience LettersYear: 200741421551582-s2.0-3384701559817258395
52. Keck ME,Kern N,Erhardt A,et al. Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorderAmerican Journal of Medical Genetics BYear: 20081477119612042-s2.0-55349106933
53. Bradley RG,Binder EB,Epstein MP,et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor geneArchives of General PsychiatryYear: 20086521902002-s2.0-3894915916318250257
54. Binneman B,Feltner D,Kolluri S,Shi Y,Qiu R,Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depressionAmerican Journal of PsychiatryYear: 200816556176202-s2.0-4394913452718413705
55. Caldwell HK,Lee H-J,Macbeth AH,Young WS III. Vasopressin: behavioral roles of an “original” neuropeptideProgress in NeurobiologyYear: 20088411242-s2.0-3714901677118053631
56. van Londen L,Goekoop JG,van Kempen GMJ,et al. Plasma levels of arginine vasopressin elevated in patients with major depressionNeuropsychopharmacologyYear: 19971742842922-s2.0-00308696859326754
57. Purba JS,Hoogendijk WJG,Hofman MA,Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depressionArchives of General PsychiatryYear: 19965321371432-s2.0-00300323508629889
58. Schmidt ED,Binnekade R,Janszen AWJW,Tilders FJH. Short stressor induced long-lasting increases in vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult ratsJournal of NeuroendocrinologyYear: 1996897037122-s2.0-00298123778877819
59. Volpi S,Rabadan-Diehl C,Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptationStressYear: 20047275832-s2.0-354300597115512850
60. Dinan TG,Scott LV. Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressinJournal of AnatomyYear: 200520732592642-s2.0-2494457183816185250
61. Dempster EL,Burcescu I,Wigg K,et al. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disordersArchives of General PsychiatryYear: 20076410118911952-s2.0-3494887953317909131
62. Egashira N,Tanoue A,Matsuda T,et al. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout miceBehavioural Brain ResearchYear: 200717811231272-s2.0-3384695180917227684
63. Bleickardt CJ,Mullins DE,MacSweeney CP,et al. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behaviorPsychopharmacologyYear: 200920247117182-s2.0-5984911165518923820
64. Aguilera G,Subburaju S,Young S,Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stressProgress in Brain ResearchYear: 200817029392-s2.0-4754908572818655869
65. Simon NG,Guillon C,Fabio K,et al. Vasopressin antagonists as anxiolytics and antidepressants: recent developmentsRecent Patents on CNS Drug DiscoveryYear: 20083277932-s2.0-4914910326518537767
66. Pedersen CA,Boccia ML. Oxytocin antagonism alters rat dams’ oral grooming and upright posturing over pupsPhysiology & BehaviorYear: 2003802-32332412-s2.0-034415393514637221
67. Benelli A,Bertolini A,Poggioli R,Menozzi B,Basaglia R,Arletti R. Polymodal dose-response curve for oxytocin in the social recognition testNeuropeptidesYear: 19952842512552-s2.0-00289584827596490
68. Rimmele U,Hediger K,Heinrichs M,Klaver P. Oxytocin makes a face in memory familiarJournal of NeuroscienceYear: 200929138422-s2.0-5814938338319129382
69. Stachowiak A,Macchi C,Nussdorfer GG,Malendowicz LK. Effects of oxytocin on the function and morphology of the rat adrenal cortex: in vitro and in vivo investigationsResearch in Experimental MedicineYear: 199519552652742-s2.0-00288859608578002
70. Legros J-J. Inhibitory effect of oxytocin on corticotrope function in humans: are vasopressin and oxytocin ying-yang neurohormones?PsychoneuroendocrinologyYear: 20012676496552-s2.0-003490718811500247
71. Ring RH,Malberg JE,Potestio L,et al. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implicationsPsychopharmacologyYear: 200618522182252-s2.0-3364484849316418825
72. Ring RH,Schechter LE,Leonard SK,et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonistNeuropharmacologyYear: 201058169772-s2.0-7154913679219615387
73. Kirsch P,Esslinger C,Chen Q,et al. Oxytocin modulates neural circuitry for social cognition and fear in humansJournal of NeuroscienceYear: 2005254911489114932-s2.0-3054443886616339042
74. Scantamburlo G,Hansenne M,Fuchs S,et al. Plasma oxytocin levels and anxiety in patients with major depressionPsychoneuroendocrinologyYear: 20073244074102-s2.0-3424725727317383107
75. Uvnas-Moberg K,Alster P,Svensson TH. Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in ratsPsychopharmacologyYear: 199210944734762-s2.0-00264603191365865
76. Jokinen J,Chatzittofis A,Hellström C,Nordström P,Uvnäs-Moberg K,Åsberg M. Low CSF oxytocin reflects high intent in suicide attemptersPsychoneuroendocrinologyYear: 20123744824902-s2.0-8485719268521852050
77. Feifel D,Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gatingPsychopharmacologyYear: 1999141193982-s2.0-00329645819952070
78. Feifel D,MacDonald K,Nguyen A,et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patientsBiological PsychiatryYear: 20106876786802-s2.0-7795693218620615494
79. Modahl C,Green L,Fein D,et al. Plasma oxytocin levels in autistic childrenBiological PsychiatryYear: 19984342702772-s2.0-00325195239513736
80. Yrigollen CM,Han SS,Kochetkova A,et al. Genes controlling affiliative behavior as candidate genes for autismBiological PsychiatryYear: 200863109119162-s2.0-4264909442518207134
81. Hollander E,Bartz J,Chaplin W,et al. Oxytocin increases retention of social cognition in autismBiological PsychiatryYear: 20076144985032-s2.0-3384662463316904652
82. Hollander E,Novotny S,Hanratty M,et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disordersNeuropsychopharmacologyYear: 20032811931982-s2.0-003720915912496956
83. Lindqvist D,Janelidze S,Erhardt S,Träskman-Bendz L,Engström G,Brundin L. CSF biomarkers in suicide attempters—a principal component analysisActa Psychiatrica ScandinavicaYear: 2011124152612-s2.0-7995874334221198458
84. Stanley B,Sher L,Wilson S,Ekman R,Huang Y-Y,Mann JJ. Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmittersJournal of Affective DisordersYear: 20101241-21341402-s2.0-7795228948219942295
85. Brundin L,Björkqvist M,Träskman-Bendz L,Petersén A. Increased orexin levels in the cerebrospinal fluid the first year after a suicide attemptJournal of Affective DisordersYear: 200911317918218533274
86. Pitchot W,Scantamburlo G,Pinto E,et al. Vasopressin-neurophysin and DST in major depression: relationship with suicidal behaviorJournal of Psychiatric ResearchYear: 20084286846882-s2.0-4304914309117720191
87. Brundin L,Björkqvist M,Petersén Å,Träskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorderEuropean NeuropsychopharmacologyYear: 20071795735792-s2.0-3444753174517346943
88. Brundin L,Petersén A,Bjِrkqvist M,Träskman-Bendz L. Orexin and psychiatric symptoms in suicide attemptersJournal of Affective DisordersYear: 20071001–325926317141878
89. Austin MC,Janosky JE,Murphy HA. Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide menMolecular PsychiatryYear: 2003833243322-s2.0-003749968012660805
90. Merali Z,Kent P,Du L,et al. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjectsBiological PsychiatryYear: 20065975946022-s2.0-3364482248816197926
91. Brunner J,Keck ME,Landgraf R,Uhr M,Namendorf C,Bronisch T. Vasopressin in CSF and plasma in depressed suicide attempters: preliminary resultsEuropean NeuropsychopharmacologyYear: 20021254894942-s2.0-003678887012208567
92. Caberlotto L,Hurd YL. Neuropeptide Y Y1 and Y2 receptor mRNA expression in the prefrontal cortex of psychiatric subjects: relationship of Y2 subtype to suicidal behaviorNeuropsychopharmacologyYear: 200125191972-s2.0-003500234911377922
93. Inder WJ,Donald RA,Prickett TCR,et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depressionBiological PsychiatryYear: 19974287447472-s2.0-00308618249325570
94. Olsson A,Regnéll G,Träskman-Bendz L,Ekman R,Westrin Å. Cerebrospinal neuropeptide Y and substance P in suicide attempters during long-term antidepressant treatmentEuropean NeuropsychopharmacologyYear: 20041464794852-s2.0-1034422262115589387
95. Westrin A,Ekman R,Regnéll G,Träskman-Bendz L. A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRHEuropean NeuropsychopharmacologyYear: 20011121351432-s2.0-003505871111313159
96. Westrin Å,Ekman R,Träskman-Bendz L. High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorderBiological PsychiatryYear: 199843107347392-s2.0-00325238279606527
97. Westrin Å,Engstöm G,Ekman R,Träskman-Bendz L. Correlations between plasma-neuropeptides and temperament dimensions differ between suicidal patients and healthy controlsJournal of Affective DisordersYear: 199849145542-s2.0-00320544489574859
98. Roy A. Neuropeptides in relation to suicidal behavior in depressionNeuropsychobiologyYear: 19932841841862-s2.0-00273768227903797
99. Ordway GA,Stockmeier CA,Meltzer HY,Overholser JC,Jaconetta S,Widdowson PS. Neuropeptide Y in frontal cortex is not altered in major depressionJournal of NeurochemistryYear: 1995654164616502-s2.0-00291031637561860
100. Träskman-Bendz L,Ekman R,Regnéll G,Öhman R. HPA-related CSF neuropeptides in suicide attemptersEuropean NeuropsychopharmacologyYear: 199222991062-s2.0-00268707661378770
101. Scarone S,Gambini O,Calabrese G,et al. Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary dataPsychiatry ResearchYear: 19903221591662-s2.0-00253329192142310
102. Maes M,Vandewoude M,Schotte C,et al. Hypothalamic-pituitary-adrenal and -thyroid axis dysfunctions and decrements in the availability of L-tryptophan as biological markers of suicidal ideation in major depressed femalesActa Psychiatrica ScandinavicaYear: 198980113172-s2.0-00243701342548371
103. Kuteeva E,Hökfelt T,Wardi T,Ogren SO. Galanin, galanin receptor subtypes and depression-like behaviourCellular and Molecular Life SciencesYear: 20086512185418632-s2.0-4584913202018500640
104. Karlsson R-M,Holmes A. Galanin as a modulator of anxiety and depression and a therapeutic target for affective diseaseAmino AcidsYear: 20063132312392-s2.0-3374957473716733616
105. Tortorella C,Neri G,Nussdorfer GG. Galanin in the regulation of the hypothalamic-pituitary-adrenal axis (review)International Journal of Molecular MedicineYear: 20071946396472-s2.0-3424789550717334639
106. Ogren SO,Kuteeva E,Hökfelt T,Kehr J. Galanin receptor antagonists: a potential novel pharmacological treatment for mood disordersCNS DrugsYear: 20062086336542-s2.0-3374656458016863269
107. Weiss JM,Boss-Williams KA,Moore JP,Demetrikopoulos MK,Ritchie JC,West CHK. Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galaninNeuropeptidesYear: 20053932812872-s2.0-2044440228415944023
108. Ogren SO,Razani H,Elvander-Tottie E,Kehr J. The neuropeptide galanin as an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disordersPhysiology & BehaviorYear: 2007921-21721792-s2.0-3454848415817585970
109. Swanson CJ,Blackburn TP,Zhang X,et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299Proceedings of the National Academy of Sciences of the United States of AmericaYear: 20051024817489174942-s2.0-2844449667216287967
110. Elliott-Hunt CR,Pope RJP,Vanderplank P,Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damageJournal of NeurochemistryYear: 200710037807892-s2.0-3384622639617263796
111. Ebner K,Muigg P,Singewald G,Singewald N. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitryAnnals of the New York Academy of SciencesYear: 2008114461732-s2.0-5664910531419076365
112. Blier P,Gobbi G,Haddjeri N,Santarelli L,Mathew G,Hen R. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic responseJournal of Psychiatry and NeuroscienceYear: 20042932082182-s2.0-304261163815173897
113. Ma Q-P,Bleasdale C. Modulation of brain stem monoamines and γ-aminobutyric acid by NKI receptors in ratsNeuroReportYear: 20021314180918122-s2.0-003703811712395129
114. Ebner K,Singewald N. Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline releaseNaunyn-Schmiedeberg’s Archives of PharmacologyYear: 20073761-273822-s2.0-38449098153
115. Ebner K,Rupniak NM,Saria A,Singewald N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in ratsProceedings of the National Academy of Sciences of the United States of AmericaYear: 200410112428042852-s2.0-164248833115024126
116. Ebner K,Sartori SB,Singewald N. Tachykinin receptors as therapeutic targets in stress-related disordersCurrent Pharmaceutical DesignYear: 20091514164716742-s2.0-6765056945719442179
117. Furmark T,Appel L,Michelgård Å,et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placeboBiological PsychiatryYear: 20055821321422-s2.0-2244444293716038684
118. Louis C,Stemmelin J,Boulay D,Bergis O,Cohen C,Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-modelsPharmacology Biochemistry and BehaviorYear: 200889136452-s2.0-38049103986
119. Smith PW,Dawson LA. Neurokinin 3 (NK3) receptor modulators for the treatment of psychiatric disordersRecent Patents on CNS Drug DiscoveryYear: 2008311152-s2.0-3894913143818221236
120. Sawchenko PE,Swanson LW,Grzanna R. Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamusJournal of Comparative NeurologyYear: 198524121381532-s2.0-00224099783840810
121. Redrobe JP,Dumont Y,Fournier A,Baker GB,Quirion R. Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim testPeptidesYear: 2005268139414002-s2.0-2254448172416042979
122. Heilig M,Soderpalm B,Engel JA,Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety modelsPsychopharmacologyYear: 19899845245292-s2.0-00243100892570434
123. Kask A,Harro J,von Hörsten S,Redrobe JP,Dumont Y,Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide YNeuroscience & Biobehavioral ReviewsYear: 20022632592832-s2.0-003611112412034130
124. Nakajima M,Inui A,Asakawa A,et al. Neuropeptide Y produces anxiety via Y2-type receptorsPeptidesYear: 19981923593632-s2.0-00320051279493869
125. Sørensen G,Lindberg C,Wörtwein G,Bolwig TG,Woldbye DPD. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedationJournal of Neuroscience ResearchYear: 20047757237292-s2.0-444434601215352219
126. Heilig M. The NPY system in stress, anxiety and depressionNeuropeptidesYear: 20043842132242-s2.0-434462237915337373
127. Sajdyk TJ,Fitz SD,Shekhar A. The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the ratStressYear: 20069121282-s2.0-3374499942916753930
128. Eaton K,Sallee FR,Sah R. Relevance of neuropeptide Y (NPY) in psychiatryCurrent Topics in Medicinal ChemistryYear: 2007717164516592-s2.0-3624894621717979774
129. Lindefors N,Linden A,Brene S,Sedvall G,Persson H. CCK peptides and mRNA in the human brainProgress in NeurobiologyYear: 19934066716902-s2.0-00274767298484007
130. Vaccarino FJ,Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral–caudal differences in accumbens CCK functionBehavioral NeuroscienceYear: 198910348318362-s2.0-00244421982765186
131. Crawley JN. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathwayJournal of NeuroscienceYear: 1992129338033912-s2.0-00267832851527584
132. Goldstein A,Fischli W,Lowney LI,Hunkapiller M,Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptideProceedings of the National Academy of Sciences of the United States of AmericaYear: 19817811721972232-s2.0-00196383806118870
133. Hegadoren KM,O’Donnell T,Lanius R,Coupland NJ,Lacaze-Masmonteil N. The role of β-endorphin in the pathophysiology of major depressionNeuropeptidesYear: 20094353413532-s2.0-7035010489219647870
134. De Lecea L,Kilduff TS,Peyron C,et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activityProceedings of the National Academy of Sciences of the United States of AmericaYear: 19989513223272-s2.0-00083902669419374
135. Date Y,Ueta Y,Yamashita H,et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systemsProceedings of the National Academy of Sciences of the United States of AmericaYear: 19999627487532-s2.0-00335821759892705
136. Nambu T,Sakurai T,Mizukami K,Hosoya Y,Yanagisawa M,Goto K. Distribution of orexin neurons in the adult rat brainBrain ResearchYear: 19998271-22432602-s2.0-003353574710320718
137. Sakurai T,Amemiya A,Ishii M,et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviorCellYear: 19989245735852-s2.0-202443800149491897
138. Stanley B,Traskman-Bendz L,Stanley M. The suicide assessment scale: a scale evaluating change in suicidal behaviorPsychopharmacology BulletinYear: 19862212002052-s2.0-00225699973726067
139. Dumont Y,Morales-Medina JC,Quirion R. Shioda S,Homma I,Kato NNeuropeptide Y and its role in anxiety-related disordersTransmitters and Modulators In Health and DiseaseYear: 2009Springer, Kato Bunmeisha5182
140. Thakker-Varia S,Alder J. Neuropeptides in depression: role of VGFBehavioural Brain ResearchYear: 200919722622782-s2.0-5814951228818983874
141. Kuteeva E,Wardi T,Lundström L,et al. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body levelNeuropsychopharmacologyYear: 20083311257325852-s2.0-5174909505318172432
142. Biguet NF,Buda M,Lamouroux A,Samolyk D,Mallet J. Time course of the changes of TH mRNA in rat brain and adrenal medulla after a single injection of reserpineThe EMBO JournalYear: 1986522872912-s2.0-00226657992872048
143. Berod A,Biguet NF,Dumas S,Bloch B,Mallet J. Modulation of tyrosine hydroxylase gene expression in the central nervous system visualized by in situ hybridizationProceedings of the National Academy of Sciences of the United States of AmericaYear: 1987846169917032-s2.0-00231947802882513
144. Holmes PV,Caroline Blanchard D,Blanchard RJ,Brady LS,Crawley JN. Chronic social stress increases levels of preprogalanin mRNA in the rat locus coeruleusPharmacology Biochemistry and BehaviorYear: 19955046556602-s2.0-0028953414
145. Morales-Medina JC,Dumont Y,Quirion R. A possible role of neuropeptide Y in depression and stressBrain ResearchYear: 201013141942052-s2.0-7514911451519782662
146. Griebel G,Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Nature Review Drug DiscoveryYear: 201211462478

Article Categories:
  • Review Article


Previous Document:  Effect of low refocusing angle in t1-weighted spin echo and fast spin echo MRI on low-contrast detec...
Next Document:  Effects of a rehabilitation program on perceived environmental barriers in older patients recovering...